{"id":"enoxaparin-sodium-xrp4563","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The low-molecular-weight formulation provides more predictable pharmacokinetics and predominantly anti-Xa activity compared to unfractionated heparin.","oneSentence":"Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:56.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis in surgical patients"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"},{"name":"Prevention of thromboembolic complications in atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT00685958","phase":"PHASE3","title":"Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Hip Fractures","enrollment":54},{"nctId":"NCT00077792","phase":"PHASE3","title":"Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-10","conditions":"Myocardial Infarction, Acute ST-Segment Elevation","enrollment":20506},{"nctId":"NCT00349180","phase":"PHASE3","title":"Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Arthroplasty, Replacement, Hip","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Enoxaparin sodium (XRP4563)","genericName":"Enoxaparin sodium (XRP4563)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}